Ralph E Navarro1, Danielle Golub2, Travis Hill1, Michelle W McQuinn1, Christopher William3, David Zagzag1,3, Eveline Teresa Hidalgo1. 1. Division of Pediatric Neurosurgery, Department of Neurosurgery, NYU Grossman School of Medicine, NYU Langone Health, New York, NY, USA. 2. Department of Neurosurgery, Zucker School of Medicine at Hofstra/Northwell, Northwell Health, 300 Community Drive, 9 Tower, Manhasset, NY, 11030, USA. Dgolub1@northwell.edu. 3. Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health, New York, NY, USA.
Abstract
BACKGROUND: H3K27M-mutant midline lesions were recently reclassified by the World Health Organization (WHO) as "diffuse midline glioma" (DMG) based entirely on their molecular signature. DMG is one of the most common and most lethal pediatric brain tumors; terminal progression is typically caused by local midbrain or brainstem progression, or secondary leptomeningeal dissemination. H3K27M mutations have also been infrequently associated with a histologically and prognostically diverse set of lesions, particularly spinal masses with early leptomeningeal spread. CASE PRESENTATION: A 15-year-old girl after 1 week of symptoms was found to have a T2/FLAIR-hyperintense and contrast-enhancing thalamic mass accompanied by leptomeningeal enhancement along the entire neuraxis. Initial infectious workup was negative, and intracranial biopsy was inconclusive. Spinal arachnoid biopsy revealed an H3K27M-mutant lesion with glioneuronal features, classified thereafter as DMG. She received craniospinal irradiation with a boost to the thalamic lesion. Imaging 1-month post-radiation demonstrated significant treatment response with residual enhancement at the conus. CONCLUSIONS: This case report describes the unique presentation of an H3K27M-mutant midline lesion with significant craniospinal leptomeningeal spread on admission and atypical glioneuronal histopathological markers. With such florid leptomeningeal disease, spinal dural biopsy should be considered earlier given its diagnostic yield in classifying the lesion as DMG. Consistent with similar prior reports, this lesion additionally demonstrated synaptophysin positivity-also potentially consistent with a diagnosis of diffuse leptomeningeal glioneuronal tumor (DLGNT). In atypical DMG cases, particularly with leptomeningeal spread, further consideration of clinical and histopathological context is necessary for accurate diagnosis and prognostication.
BACKGROUND: H3K27M-mutant midline lesions were recently reclassified by the World Health Organization (WHO) as "diffuse midline glioma" (DMG) based entirely on their molecular signature. DMG is one of the most common and most lethal pediatric brain tumors; terminal progression is typically caused by local midbrain or brainstem progression, or secondary leptomeningeal dissemination. H3K27M mutations have also been infrequently associated with a histologically and prognostically diverse set of lesions, particularly spinal masses with early leptomeningeal spread. CASE PRESENTATION: A 15-year-old girl after 1 week of symptoms was found to have a T2/FLAIR-hyperintense and contrast-enhancing thalamic mass accompanied by leptomeningeal enhancement along the entire neuraxis. Initial infectious workup was negative, and intracranial biopsy was inconclusive. Spinal arachnoid biopsy revealed an H3K27M-mutant lesion with glioneuronal features, classified thereafter as DMG. She received craniospinal irradiation with a boost to the thalamic lesion. Imaging 1-month post-radiation demonstrated significant treatment response with residual enhancement at the conus. CONCLUSIONS: This case report describes the unique presentation of an H3K27M-mutant midline lesion with significant craniospinal leptomeningeal spread on admission and atypical glioneuronal histopathological markers. With such florid leptomeningeal disease, spinal dural biopsy should be considered earlier given its diagnostic yield in classifying the lesion as DMG. Consistent with similar prior reports, this lesion additionally demonstrated synaptophysin positivity-also potentially consistent with a diagnosis of diffuse leptomeningeal glioneuronal tumor (DLGNT). In atypical DMG cases, particularly with leptomeningeal spread, further consideration of clinical and histopathological context is necessary for accurate diagnosis and prognostication.
Authors: Tabitha M Cooney; Kenneth J Cohen; Carolina V Guimaraes; Girish Dhall; James Leach; Maura Massimino; Alessandra Erbetta; Luisa Chiapparini; Fatema Malbari; Kim Kramer; Ian F Pollack; Patricia Baxter; Suzanne Laughlin; Zoltán Patay; Tina Young Poussaint; Katherine E Warren Journal: Lancet Oncol Date: 2020-06 Impact factor: 41.316
Authors: Sahaja Acharya; Jo-Fen Liu; Ruth G Tatevossian; Jason Chiang; Ibrahim Qaddoumi; Amar Gajjar; David Walker; Julie H Harreld; Thomas E Merchant; David W Ellison Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: Sarah M Bronner; Karl A Merrick; Jeremy Murray; Laurent Salphati; John G Moffat; Jodie Pang; Christopher J Sneeringer; Nicholas Dompe; Patrick Cyr; Hans Purkey; Gladys de Leon Boenig; Jun Li; Aleksandr Kolesnikov; Robin Larouche-Gauthier; Kwong Wah Lai; Xiaoli Shen; Samuel Aubert-Nicol; Yi-Chen Chen; Jonathan Cheong; James J Crawford; Marc Hafner; Pouyan Haghshenas; Araz Jakalian; Jean-Philippe Leclerc; Ngiap-Kie Lim; Tom O'Brien; Emile G Plise; Hadil Shalan; Claudio Sturino; John Wai; Yang Xiao; Jianping Yin; Liang Zhao; Stephen Gould; Alan Olivero; Timothy P Heffron Journal: Bioorg Med Chem Lett Date: 2019-06-26 Impact factor: 2.823
Authors: Bettina L Serrallach; Brandon H Tran; David F Bauer; Carrie A Mohila; Adekunle M Adesina; Susan L McGovern; Holly B Lindsay; Thierry Agm Huisman Journal: Neuroradiol J Date: 2022-01-06